146 related articles for article (PubMed ID: 8937969)
1. Comparative in-vitro activity of cefoperazone/sulbactam and 11 other agents against multidrug resistant Bacteroides fragilis group species.
Goldstein EJ; Citron DM
J Antimicrob Chemother; 1996 Oct; 38(4):733-7. PubMed ID: 8937969
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory and bactericidal activity of selected beta-lactam agents alone and in combination with beta-lactamase inhibitors compared with that of cefoxitin and metronidazole against cefoxitin-susceptible and cefoxitin-resistant isolates of the Bacteroides fragilis group.
Stratton CW; Weeks LS; Aldridge KE
Diagn Microbiol Infect Dis; 1992; 15(4):321-30. PubMed ID: 1611847
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of cefoperazone/sulbactam and other antimicrobials against anaerobic bacteria.
D'Amato RF; Hochstein L; Frankel H
Diagn Microbiol Infect Dis; 1990; 13(1):51-5. PubMed ID: 2331850
[TBL] [Abstract][Full Text] [Related]
4. Susceptibilities of 394 Bacteroides fragilis, non-B. fragilis group Bacteroides species, and Fusobacterium species to newer antimicrobial agents.
Appelbaum PC; Spangler SK; Jacobs MR
Antimicrob Agents Chemother; 1991 Jun; 35(6):1214-8. PubMed ID: 1929264
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of cefoperazone plus sulbactam compared with that of other antimicrobial agents against anaerobic bacteria.
Wexler HM; Finegold SM
Antimicrob Agents Chemother; 1988 Mar; 32(3):403-6. PubMed ID: 3364960
[TBL] [Abstract][Full Text] [Related]
6. Comparative susceptibility of the Bacteroides fragilis group species and other anaerobic bacteria to meropenem, imipenem, piperacillin, cefoxitin, ampicillin/sulbactam, clindamycin and metronidazole.
Goldstein EJ; Citron DM; Cherubin CE; Hillier SL
J Antimicrob Chemother; 1993 Mar; 31(3):363-72. PubMed ID: 8486570
[TBL] [Abstract][Full Text] [Related]
7. In-vitro study of the susceptibility of cefoxitin/cefotetan resistant Bacteroides fragilis group strains to various other antimicrobial agents.
Aldridge KE; Henderberg A; Sanders CV
J Antimicrob Chemother; 1990 Sep; 26(3):353-9. PubMed ID: 2228826
[TBL] [Abstract][Full Text] [Related]
8. Cross-resistance to beta-lactam-beta-lactamase inhibitor combinations and clindamycin among cefoxitin-resistant and cefoxitin-susceptible strains of the Bacteroides fragilis group.
Aldridge KE
Diagn Microbiol Infect Dis; 1993 Oct; 17(3):251-6. PubMed ID: 8112038
[TBL] [Abstract][Full Text] [Related]
9. Newer beta-lactam agents and the Bacteroides fragilis group.
Cuchural GJ
Pharmacotherapy; 1991; 11(2 ( Pt 2)):51S-55S. PubMed ID: 2041832
[TBL] [Abstract][Full Text] [Related]
10. beta-Lactamase inhibition and in vitro activity of sulbactam and sulbactam/cefoperazone.
Williams JD
Clin Infect Dis; 1997 Mar; 24(3):494-7. PubMed ID: 9114205
[TBL] [Abstract][Full Text] [Related]
11. The antimicrobial susceptibility patterns of the Bacteroides fragilis group in the United States, 1987.
Cornick NA; Cuchural GJ; Snydman DR; Jacobus NV; Iannini P; Hill G; Cleary T; O'Keefe JP; Pierson C; Finegold SM
J Antimicrob Chemother; 1990 Jun; 25(6):1011-9. PubMed ID: 2370237
[TBL] [Abstract][Full Text] [Related]
12. Susceptibilities of anaerobic gram-negative bacilli to thirteen antimicrobials and beta-lactamase inhibitor combinations.
Hill GB; Ayers OM; Everett BQ
J Antimicrob Chemother; 1991 Dec; 28(6):855-67. PubMed ID: 1816182
[TBL] [Abstract][Full Text] [Related]
13. In-vitro susceptibilities of species of the Bacteroides fragilis group to newer beta-lactam agents.
Betriu C; Sánchez A; Gómez M; Palau ML; Picazo JJ
J Antimicrob Chemother; 1999 Jan; 43(1):133-6. PubMed ID: 10381111
[TBL] [Abstract][Full Text] [Related]
14. In vitro comparison of cefoperazone/sulbactam with selected antimicrobials against 300 bacteroides isolates. Inhibitory activity and time-kill kinetic studies.
Gelfand MS; Grogan JT; Haas MJ
Diagn Microbiol Infect Dis; 1989; 12(5):421-8. PubMed ID: 2612130
[TBL] [Abstract][Full Text] [Related]
15. [Comparative in vitro activity of ampicillin, cefoperazone and their combinations with sulbactam, as well as that of other antibiotics against anaerobic organisms].
Rezvan SP; Sidorenko SV; Budanov SV
Antibiot Khimioter; 1995 Apr; 40(4):25-9. PubMed ID: 7654095
[TBL] [Abstract][Full Text] [Related]
16. Effect of beta-lactamase inhibitors on the antimicrobial activity of cefoperazone, cefotaxime, and ceftizoxime against aerobic and anaerobic beta-lactamase producing bacteria.
Fuchs PC; Jones RN; Barry AL
Diagn Microbiol Infect Dis; 1987 Sep; 8(1):61-5. PubMed ID: 3501975
[TBL] [Abstract][Full Text] [Related]
17. Multicentre study on antibiotic susceptibilities of anaerobic bacteria to cefoperazone-sulbactam and other antimicrobial agents.
Clark RB; Bartelt MA; Chan EL; Dalton HP
J Antimicrob Chemother; 1992 Jan; 29(1):57-67. PubMed ID: 1737725
[TBL] [Abstract][Full Text] [Related]
18. [In vitro antibacterial activity of cefoperazone-sulbactam].
Zhang Y; Zhang J; Zhou L
Zhonghua Nei Ke Za Zhi; 1995 Oct; 34(10):676-9. PubMed ID: 8731829
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of cefoperazone-sulbactam: Singapore experience.
Kumarasinghe G; Chow C; Chiu C; Cheong YM
Southeast Asian J Trop Med Public Health; 1996 Dec; 27(4):734-7. PubMed ID: 9253876
[TBL] [Abstract][Full Text] [Related]
20. In-vitro activity of cefoperazone-sulbactam against Bacteroides species.
Souza Dias MB; Jacobus NV; Tally FP
J Antimicrob Chemother; 1986 Oct; 18(4):467-71. PubMed ID: 3021709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
